Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations

被引:220
作者
Moran, A. [2 ]
O'Hara, C. [2 ]
Khan, S. [2 ]
Shack, L. [2 ,3 ]
Woodward, E. [4 ,5 ]
Maher, E. R. [4 ,5 ]
Lalloo, F. [1 ]
Evans, D. G. R. [1 ]
机构
[1] St Marys Hosp, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England
[2] Christie NHS Fdn Trust, NW Canc Intelligence Serv, Manchester M20 3LJ, Lancs, England
[3] Univ Calgary, Calgary, AB, Canada
[4] Univ Birmingham, Ctr Rare Dis & Personalised Med, Sch Med, Birmingham B15 2TT, W Midlands, England
[5] Birmingham Womens Hosp, W Midlands Reg Genet Serv, Clin Genet Unit, Birmingham B15 2TG, W Midlands, England
基金
美国国家卫生研究院;
关键词
BRCA1; BRCA2; Pancreatic cancer; Prostate cancer; Oesophageal cancer; Uveal melanoma; GERMLINE MUTATIONS; PENETRANCE; FAMILIES; CARRIERS;
D O I
10.1007/s10689-011-9506-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The risks of cancers other than breast and ovarian amongst BRCA1 and BRCA2 mutation carriers are based on relatively few family based studies with the risk of specific cancers tested in population based samples of cancers from founder populations. We assessed risks of "other cancers" in 268 BRCA1 families and 222 BRCA2 families using a person years at risk analysis from 1975 to 2005. Cancer confirmations were overall higher than in previous family based studies at 64%. There was no overall increase in risk for BRCA1 carriers although oesophagus had a significant increased RR of 2.9 (95% CI 1.1-6.0) and stomach at 2.4 (95% CI 1.2-4.3), these were based mainly on unconfirmed cases. For BRCA2 increased risks for cancers of the pancreas (RR 4.1, 95% CI 1.9-7.8) and prostate (RR 6.3, 95% CI 4.3-9.0) and uveal melanoma (RR 99.4, 95% CI 11.1-359.8) were confirmed. Possible new associations with oesophagus (RR 4.1, 95% CI 1.9-7.8) and stomach (RR 2.7, 95% CI 1.3-4.8) were detected but these findings should be treated with caution due to lower confirmation rates. In contrast to previous research a higher risk of prostate cancer was found in males with mutations in the BRCA2 OCCR region. The present study strengthens the known links between BRCA2 and pancreatic and prostate cancer, but throws further doubt onto any association with BRCA1. New associations with upper gastro-intestinal malignancy need to be treated with caution and confirmed by large prospective studies.
引用
收藏
页码:235 / 242
页数:8
相关论文
共 27 条
[1]   Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma [J].
Akbari, M. R. ;
Malekzadeh, R. ;
Nasrollahzadeh, D. ;
Amanian, D. ;
Islami, F. ;
Li, S. ;
Zandvakili, I. ;
Shakeri, R. ;
Sotoudeh, M. ;
Aghceli, K. ;
Salahi, R. ;
Pourshams, A. ;
Semnani, S. ;
Boffetta, P. ;
Dawsey, S. M. ;
Ghadirian, P. ;
Narod, S. A. .
ONCOGENE, 2008, 27 (09) :1290-1296
[2]   Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations:: a combined analysis of 22 population based studies [J].
Antoniou, AC ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (07) :602-603
[3]  
Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
[4]  
Breslow NE., 1987, STAT METHODS CANC RE, V1
[5]   Characterization of BRCA1 and BRCA2 mutations in a large United States sample [J].
Chen, SN ;
Iversen, ES ;
Friebel, T ;
Finkelstein, D ;
Weber, BL ;
Eisen, A ;
Peterson, LE ;
Schildkraut, JM ;
Isaacs, C ;
Peshkin, BN ;
Corio, C ;
Leondaridis, L ;
Tomlinson, G ;
Dutsm, D ;
Kerber, R ;
Amos, CI ;
Strong, LC ;
Berry, DA ;
Euthus, DM ;
Parmigiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :863-871
[6]   BRCA1 mutations and prostate cancer in Poland [J].
Cybulski, Cezary ;
Gorski, Bohdan ;
Gronwald, Jacek ;
Huzarski, Tornasz ;
Byrski, Tornasz ;
Debniak, Tadeusz ;
Jakubowsk, Anna ;
Wokotorczyk, Dominika ;
Gliniewicz, Bartlomiej ;
Sikorski, Andrzej ;
Stawicka, Malgorzata ;
Godlewski, Dariusz ;
Kwias, Zbigniew ;
Antczak, Andrzej ;
Krajka, Kazimierz ;
Lauer, Wojciech ;
Sosnowski, Marek ;
Sikorska-Radek, Paulina ;
Bar, Krzysztof ;
Klijer, Robert ;
Romuald, Zdrojowy ;
Malkiewicz, Bartosz ;
Borkowski, Andrzej ;
Borkowski, Tomasz ;
Szwiec, Marek ;
Posmyk, Michal ;
Narod, Steven A. ;
Lubinski, Jan .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2008, 17 (01) :62-66
[7]   Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations [J].
Dite, G. S. ;
Whittemore, A. S. ;
Knight, J. A. ;
John, E. M. ;
Milne, R. L. ;
Andrulis, I. L. ;
Southey, M. C. ;
McCredie, M. R. E. ;
Giles, G. G. ;
Miron, A. ;
Phipps, A. I. ;
West, D. W. ;
Hopper, J. L. .
BRITISH JOURNAL OF CANCER, 2010, 103 (07) :1103-1108
[8]  
Douglas FS, 1999, J MED GENET, V36, P309
[9]   Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13 [J].
Easton, DF ;
Steele, L ;
Fields, P ;
Ormiston, W ;
Averill, D ;
Daly, PA ;
McManus, R ;
Neuhausen, SL ;
Ford, D ;
Wooster, R ;
CannonAlbright, LA ;
Stratton, MR ;
Goldgar, DE .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (01) :120-128
[10]   Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting:: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family [J].
Evans, D. Gareth ;
Shenton, Andrew ;
Woodward, Emma ;
Lalloo, Fiona ;
Howell, Anthony ;
Maher, Eamonn R. .
BMC CANCER, 2008, 8 (1)